Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari M James Barrett. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa M James Barrett telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh M James Barrett. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam APPN / Appian Corporation - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam APPN / Appian Corporation - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ARDX / Ardelyx, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-06-24 | ARDX | New Enterprise Associates 12, Limited Partnership | 510,442 | 14.0000 | 510,442 | 14.0000 | 7,146,188 | 162 | 32.89 | 9,642,249 | 134.93 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ARDX / Ardelyx, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AVTX / Avalo Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AVTX / Avalo Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam BE / Bloom Energy Corporation - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-07-27 | BE | NEW ENTERPRISE ASSOCIATES 10 L P | 1,333,333 | 15.0000 | 1,333,333 | 15.0000 | 19,999,995 | 61 | 35.8 | 27,733,326 | 138.67 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam BE / Bloom Energy Corporation - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam BOX / Box, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam BOX / Box, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CSBR / Champions Oncology, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CSBR / Champions Oncology, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam DERM / Journey Medical Corporation - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam DERM / Journey Medical Corporation - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam FOLD / Amicus Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam FOLD / Amicus Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam GRPN / Groupon, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam GRPN / Groupon, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam MRSN / Mersana Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam MRSN / Mersana Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RYTM / Rhythm Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RYTM / Rhythm Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SENS / Senseonics Holdings, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SENS / Senseonics Holdings, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SUPN / Supernus Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SUPN / Supernus Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SYBX / Synlogic, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SYBX / Synlogic, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam TRVN / Trevena, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam TRVN / Trevena, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh M James Barrett sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-06-03 |
|
4 | SENS |
Senseonics Holdings, Inc.
Stock Option (right to buy) |
A - Award | 86,930 | 86,930 | |||||
2019-01-04 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
A - Award | 3,624 | 512,720 | 0.71 | 2.69 | 9,749 | 1,379,217 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | -1,124,301 | 0 | -100.00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -437,706 | 0 | -100.00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | -4,349 | 437,706 | -0.98 | 5.00 | -21,745 | 2,188,530 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
X - Other | 181,190 | 442,055 | 69.46 | 0.12 | 21,743 | 53,047 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
X - Other | -181,190 | 0 | -100.00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3,279,627 | 0 | -100.00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | -1,177 | 3,279,627 | -0.04 | 5.00 | -5,885 | 16,398,135 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
X - Other | 49,030 | 3,280,804 | 1.52 | 0.12 | 5,884 | 393,696 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
X - Other | -49,030 | 0 | -100.00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 1,800,000 | 6,641,634 | 37.18 | 5.00 | 9,000,000 | 33,208,170 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 4,841,634 | 4,841,634 | |||||
2018-10-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | 14,770 | 14,770 | |||||
2018-10-03 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
A - Award | 2,147 | 509,096 | 0.42 | 4.54 | 9,747 | 2,311,296 | |
2018-09-10 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 3,000,000 | 82,978,668 | 3.75 | 1.67 | 5,000,100 | 138,300,546 | |
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Warrant to purchase Common Stock |
J - Other | 40,702 | 40,702 | |||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Warrant to purchase Series D Preferred Stock |
J - Other | -684,911 | 0 | -100.00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series D Preferred Stock |
C - Conversion | -16,502,833 | 0 | -100.00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series C Preferred Stock |
C - Conversion | -3,337,206 | 0 | -100.00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series B Preferred Stock |
C - Conversion | -3,645,307 | 0 | -100.00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
P - Purchase | 545,455 | 2,484,870 | 28.12 | 11.00 | 6,000,005 | 27,333,570 | |
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 980,715 | 1,939,415 | 102.30 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 432,033 | 958,700 | 82.03 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 515,547 | 526,667 | 4,636.21 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 346,239 | 7,729,641 | 4.69 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
8% Convertible Preferred Notes |
C - Conversion | -346,239 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 650,631 | 7,383,402 | 9.66 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series G Convertible Preferred Stock |
C - Conversion | -650,631 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 125,989 | 6,732,771 | 1.91 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series F Convertible Preferred Stock |
C - Conversion | -125,989 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 395,815 | 6,606,782 | 6.37 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series E Convertible Preferred Stock |
C - Conversion | -395,815 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 620,155 | 6,210,967 | 11.09 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series D Convertible Preferred Stock |
C - Conversion | -620,155 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 1,062,944 | 5,590,812 | 23.48 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series C Convertible Preferred Stock |
C - Conversion | -1,062,944 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 4,527,868 | 4,527,868 | |||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series B Convertible Preferred Stock |
C - Conversion | -4,527,868 | 0 | -100.00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class A Common Stock |
P - Purchase | 1,333,333 | 1,333,333 | 15.00 | 19,999,995 | 19,999,995 | ||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22,240 | ||||||||
2018-07-05 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
A - Award | 2,200 | 506,949 | 0.44 | 4.43 | 9,746 | 2,245,784 | |
2018-06-19 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Stock Option (Right to Buy) |
A - Award | 15,300 | 15,300 | |||||
2018-06-01 |
|
4 | SENS |
Senseonics Holdings, Inc.
Stock Option (right to buy) |
A - Award | 50,847 | 50,847 | |||||
2018-05-30 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 416,667 | 9,169,210 | 4.76 | 4.00 | 1,666,668 | 36,676,840 | |
2018-05-21 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11,000 | 11,000 | |||||
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Warrant to Purchase Common Stock (right to buy) |
X - Other | -298,406 | 0 | -100.00 | ||||
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Warrant to Purchase Common Stock (right to buy) |
X - Other | -216,046 | 0 | -100.00 | ||||
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
S - Sale | -5,533 | 4,995,664 | -0.11 | 17.81 | -98,543 | 88,972,776 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
X - Other | 298,406 | 5,001,197 | 6.35 | 0.33 | 98,474 | 1,650,395 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
S - Sale | -4,006 | 4,702,791 | -0.09 | 17.81 | -71,347 | 83,756,708 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
X - Other | 216,046 | 4,706,797 | 4.81 | 0.33 | 71,295 | 1,553,243 | |
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
C - Conversion | -12,679,970 | 0 | -100.00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
U - Other | -12,679,970 | 0 | -100.00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
C - Conversion | 12,679,970 | 12,679,970 | |||||
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -6,995,000 | 0 | -100.00 | ||||
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
P - Purchase | 133,333 | 3,312,877 | 4.19 | 15.00 | 1,999,995 | 49,693,155 | |
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
C - Conversion | 3,179,544 | 3,179,544 | |||||
2018-04-09 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
A - Award | 3,145 | 504,749 | 0.63 | 3.10 | 9,750 | 1,564,722 | |
2018-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 6,000,000 | 79,978,672 | 8.11 | 1.92 | 11,500,200 | 153,295,121 | |
2018-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 571,164 | 73,978,672 | 0.78 | 1.90 | 1,087,553 | 140,862,789 | |
2018-03-27 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Warrant to Purchase Common Stock |
P - Purchase | 707,964 | 707,964 | 0.12 | 88,496 | 88,496 | ||
2018-03-27 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 707,964 | 3,466,003 | 25.67 | 2.70 | 1,911,503 | 9,358,208 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 294,090 | 73,407,508 | 0.40 | 1.95 | 572,358 | 142,865,692 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 869,574 | 73,113,418 | 1.20 | 1.90 | 1,655,669 | 139,207,948 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 104,844 | 72,243,844 | 0.15 | 1.81 | 189,820 | 130,797,480 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 12,634 | 9,681,129 | 0.13 | 59.82 | 755,708 | 579,080,604 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 17,248 | 9,668,495 | 0.18 | 59.76 | 1,030,813 | 577,829,869 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1,600 | 9,651,247 | 0.02 | 59.15 | 94,634 | 570,832,655 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 30,321 | 9,649,647 | 0.32 | 58.28 | 1,767,153 | 562,395,902 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 17,859 | 9,619,326 | 0.19 | 57.34 | 1,024,114 | 551,614,478 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 4,080 | 9,601,467 | 0.04 | 56.66 | 231,174 | 544,022,961 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 6,399 | 9,597,387 | 0.07 | 55.01 | 352,005 | 527,946,500 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 26,304 | 9,590,988 | 0.28 | 54.32 | 1,428,875 | 520,997,814 | |
2018-03-02 |
|
4 | TNTR |
Tintri, Inc.
Note Purchase Agreement (obligation to purchase) |
E - Other | 0 | ||||||
2018-02-21 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2,000,000 | 5,490,073 | 57.31 | 6.00 | 12,000,000 | 32,940,438 | |
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -2,724,202 | 0 | -100.00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 339 | 1,015 | 50.15 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 339 | 1,015 | 50.15 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 676 | 676 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 676 | 676 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -13,621 | 0 | -100.00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 13,621 | 13,621 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -27,242 | 0 | -100.00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 27,242 | 27,242 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -2,724,202 | 0 | -100.00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 2,724,202 | 2,724,202 | |||||
2018-01-26 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 410,000 | 4,228,940 | 10.74 | 9.75 | 3,997,500 | 41,232,165 | |
2018-01-09 | 3 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value |
8,282,616 | ||||||||
2018-01-09 | 3 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value |
8,282,616 | ||||||||
2018-01-04 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
A - Award | 3,665 | 501,604 | 0.74 | 2.66 | 9,749 | 1,334,267 | |
2017-12-19 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 2,000,000 | 5,554,610 | 56.26 | 5.00 | 10,000,000 | 27,773,050 | |
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -569,620 | 2,724,202 | -17.29 | ||||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
S - Sale | -569,620 | 0 | -100.00 | 19.49 | -11,101,894 | ||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 569,620 | 569,620 | |||||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -2,820,516 | 3,293,822 | -46.13 | ||||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
S - Sale | -2,820,516 | 0 | -100.00 | 19.49 | -54,971,857 | ||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 2,820,516 | 2,820,516 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 252 | 252 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 252 | 252 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | -1,000,000 | 2,256,013 | -30.71 | ||||
2017-10-16 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
A - Award | 3,250 | 497,939 | 0.66 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock |
C - Conversion | -2,927,708 | 0 | -100.00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stoc |
C - Conversion | -1,402,870 | 0 | -100.00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 550,000 | 4,909,956 | 12.61 | 17.00 | 9,350,000 | 83,469,252 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 2,927,708 | 4,359,956 | 204.41 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 1,402,870 | 1,432,248 | 4,775.24 | ||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58,756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58,756 | ||||||||
2017-08-30 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 3,394,439 | 3,818,940 | 799.63 | ||||
2017-08-07 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Stock Option (Right to Buy) |
A - Award | 63,663 | 63,663 | |||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series C-1 Preferred Stock |
C - Conversion | -2,216,626 | 0 | -100.00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -18,001,419 | 0 | -100.00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -11,931,173 | 0 | -100.00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
P - Purchase | 1,000,000 | 8,140,138 | 14.01 | 15.00 | 15,000,000 | 122,102,070 | |
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
C - Conversion | 7,140,138 | 7,140,138 | |||||
2017-06-30 |
|
4 | ROKA |
Roka BioScience, Inc.
Stock Option (right to buy) |
A - Award | -3,000 | 3,000 | -50.00 | ||||
2017-06-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | 10,000 | 10,000 | |||||
2017-06-05 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
P - Purchase | 7,092,198 | 21,911,183 | 47.86 | 1.41 | 9,999,999 | 30,894,768 | |
2017-05-31 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | 6,114,338 | 6,114,338 | |||||
2017-05-31 |
|
4 | APPN |
APPIAN CORP
Series B Convertible Preferred Stock |
C - Conversion | -6,114,338 | 0 | -100.00 | ||||
2017-05-30 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11,000 | 11,000 | |||||
2017-05-26 |
|
4 | SENS |
Senseonics Holdings, Inc.
Stock Option (right to buy) |
A - Award | 128,817 | 128,817 | |||||
2017-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 12,870,000 | 72,139,000 | 21.71 | 0.70 | 9,009,000 | 50,497,300 | |
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
J - Other | 12,679,970 | 12,679,970 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series G Preferred Stock |
C - Conversion | -605,668 | 0 | -100.00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series F Preferred Stock |
C - Conversion | -2,064,048 | 0 | -100.00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series E Preferred Stock |
C - Conversion | -8,000,038 | 0 | -100.00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series A Preferred Stock |
C - Conversion | -1,689,436 | 0 | -100.00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
J - Other | -12,679,970 | 0 | -100.00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
C - Conversion | 12,359,190 | 12,679,970 | 3,852.86 | ||||
2017-03-16 | 3 | MULE |
MULESOFT, INC
Common Stock |
641,560 | ||||||||
2017-03-16 | 3 | MULE |
MULESOFT, INC
Common Stock |
641,560 | ||||||||
2017-03-01 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 861 | 50.00 | ||||
2017-03-01 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 861 | 50.00 | ||||
2017-03-01 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -11,399 | 0 | -100.00 | ||||
2017-03-01 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 11,399 | 11,399 | |||||
2017-03-01 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1,139,890 | 0 | -100.00 | ||||
2017-02-14 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -1,099,996 | 952,809 | -53.59 | 2.01 | -2,211,432 | 1,915,527 | |
2016-11-29 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 869,565 | 2,758,039 | 46.05 | 5.75 | 4,999,999 | 15,858,724 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series B-2 Preferred Stock |
C - Conversion | -4,362,472 | 0 | -100.00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series B-1 Preferred Stock |
C - Conversion | -4,689,657 | 0 | -100.00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12,447,605 | 0 | -100.00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Warrants to Purchase Common Stock |
X - Other | -80,658 | 0 | -100.00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 338,462 | 3,490,073 | 10.74 | 13.00 | 4,400,006 | 45,370,949 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 623,210 | 3,151,611 | 24.65 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 669,951 | 2,528,401 | 36.05 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,778,227 | 1,858,450 | 2,216.60 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
S - Sale | -435 | 80,223 | -0.54 | 13.00 | -5,655 | 1,042,899 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
X - Other | 80,658 | 80,658 | 0.07 | 5,646 | 5,646 | ||
2016-09-30 |
|
4/A | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 4,000 | 4,000 | |||||
2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Warrant to Purchase Common Stock (right to buy) |
P - Purchase | 5,714,286 | 5,714,286 | |||||
2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 4,000 | 4,000 | |||||
2016-09-20 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -7,471 | 2,052,805 | -0.36 | 0.75 | -5,603 | 1,539,604 | |
2016-09-15 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -10,000 | 2,060,276 | -0.48 | 0.74 | -7,400 | 1,524,604 | |
2016-09-15 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 461,538 | 3,554,610 | 14.92 | 13.00 | 5,999,994 | 46,209,930 | |
2016-08-31 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -50,000 | 2,070,276 | -2.36 | 1.01 | -50,440 | 2,088,494 | |
2016-08-26 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -1,200 | 2,120,276 | -0.06 | 1.21 | -1,452 | 2,565,534 | |
2016-08-02 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) |
P - Purchase | 20,120,724 | 20,120,724 | |||||
2016-08-02 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
P - Purchase | 20,120,724 | 55,418,811 | 57.00 | 0.10 | 2,000,000 | 5,508,630 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -8,989 | 2,121,476 | -0.42 | 1.33 | -11,957 | 2,821,987 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -14,158 | 2,130,465 | -0.66 | 1.24 | -17,550 | 2,640,924 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -534 | 2,144,623 | -0.02 | 1.17 | -625 | 2,509,209 | |
2016-07-20 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 763,650 | 8,752,543 | 9.56 | 8.73 | 6,666,664 | 76,409,700 | |
2016-07-15 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -13,382 | 2,145,157 | -0.62 | 1.20 | -16,060 | 2,574,403 | |
2016-06-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Stock Option (right to buy) |
A - Award | -30,000 | 30,000 | -50.00 | ||||
2016-06-14 |
|
4 | OPWR |
OPOWER, INC.
Common Stock |
U - Other | -8,989,766 | 0 | -100.00 | 10.30 | -92,594,590 | ||
2016-06-13 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | 10,000 | 10,000 | |||||
2016-05-26 |
|
4 | SENS |
Senseonics Holdings, Inc.
Stock Option (right to buy) |
A - Award | 54,629 | 54,629 | |||||
2016-05-19 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11,000 | 11,000 | |||||
2016-03-24 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
G - Gift | -18,000 | 97,355 | -15.60 | ||||
2016-03-23 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
P - Purchase | 1,578,947 | 14,818,985 | 11.93 | 2.85 | 4,499,999 | 42,234,107 | |
2016-03-18 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 710,429 | 9,564,684 | 8.02 | 35.19 | 24,999,997 | 336,581,230 | |
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
14,381,495 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
14,038,885 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
27,126,844 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
14,381,495 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
14,038,885 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
27,126,844 | ||||||||
2016-03-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Director Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series B Convertible Redeemable Preferred Stock |
C - Conversion | -4,423,723 | 0 | -100.00 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series A Convertible Preferred Stock |
C - Conversion | -13,848,000 | 0 | -100.00 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 900,324 | 3,093,072 | 41.06 | 8.00 | 7,202,592 | 24,744,576 | |
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2,192,748 | 2,192,748 | |||||
2016-02-12 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Stock Option (Right to Buy) |
A - Award | 45,760 | 45,760 | |||||
2016-02-04 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
D - Sale to Issuer | -3,943,269 | 0 | -100.00 | ||||
2016-01-14 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 500,000 | 7,988,893 | 6.68 | 10.00 | 5,000,000 | 79,888,930 | |
2016-01-12 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 1,111,111 | 5,854,351 | 23.43 | 9.00 | 9,999,999 | 52,689,159 | |
2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
118,538,000 | ||||||||
2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
118,538,000 | ||||||||
2015-12-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -70,913 | 0 | -100.00 | 14.75 | -1,045,953 | ||
2015-12-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -71,067 | 70,913 | -50.05 | 14.38 | -1,022,192 | 1,019,977 | |
2015-12-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -70,990 | 141,980 | -33.33 | 14.54 | -1,032,152 | 2,064,304 | |
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 212,970 | 212,970 | |||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 8,733 | 24,317 | 56.04 | ||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 11,980 | 33,360 | 56.03 | ||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 20,713 | 57,678 | 56.03 | ||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 41,426 | 115,355 | 56.03 | ||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -1,172,932 | 0 | -100.00 | ||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 1,172,932 | 1,172,932 | |||||
2015-12-03 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -3,820,625 | 0 | -100.00 | ||||
2015-11-30 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Director Stock Option (Right to Buy) |
M - Exercise | -7,457 | 0 | -100.00 | ||||
2015-11-30 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Director Stock Option (Right to Buy) |
M - Exercise | -8,722 | 0 | -100.00 | ||||
2015-11-30 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -16,179 | 73,929 | -17.96 | 16.35 | -264,494 | 1,208,591 | |
2015-11-30 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
M - Exercise | 7,457 | 90,108 | 9.02 | 9.24 | 68,903 | 832,598 | |
2015-11-30 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8,722 | 82,651 | 11.80 | 7.90 | 68,904 | 652,943 | |
2015-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Warrant to Purchase Common Stock (right to buy) |
X - Other | -9,445 | 0 | -100.00 | 0.33 | -3,117 | ||
2015-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
S - Sale | -452 | 4,490,751 | -0.01 | 6.91 | -3,123 | 31,031,089 | |
2015-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
X - Other | 9,445 | 4,491,203 | 0.21 | 0.33 | 3,117 | 1,482,097 | |
2015-11-18 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -43,000 | 0 | -100.00 | 16.50 | -709,543 | ||
2015-11-18 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -50,000 | 43,000 | -53.76 | 16.71 | -835,460 | 718,496 | |
2015-11-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -19,650 | 93,000 | -17.44 | 16.13 | -317,035 | 1,500,471 | |
2015-11-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100,000 | 112,650 | -47.03 | 16.26 | -1,625,610 | 1,831,250 | |
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 212,650 | 212,650 | |||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 8,728 | 15,584 | 127.30 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 11,974 | 21,380 | 127.30 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 20,703 | 36,965 | 127.31 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 41,405 | 73,929 | 127.31 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -1,172,932 | 0 | -100.00 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 1,172,932 | 1,172,932 | |||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -3,820,625 | 3,820,625 | -50.00 | ||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Series B Convertible Preferred Stock |
C - Conversion | -16,638,880 | 0 | -100.00 | ||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Common Stock |
C - Conversion | 594,245 | 594,245 | |||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
P - Purchase | 857,142 | 2,971,517 | 40.54 | 7.00 | 5,999,994 | 20,800,619 | |
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
J - Other | 31,650 | 2,114,375 | 1.52 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
J - Other | 257,516 | 1,499,166 | 20.74 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -583,559 | 0 | -100.00 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,241,650 | 0 | -100.00 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
C - Conversion | 583,559 | 2,082,725 | 38.93 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
C - Conversion | 1,241,650 | 1,241,650 | |||||
2015-08-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 11,000 | 11,000 | |||||
2015-07-30 |
|
4 | LOXO |
Loxo Oncology, Inc.
Director Stock Option (right to buy) |
A - Award | 7,812 | 7,812 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 464 | 464 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 1,134 | 1,134 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
I - Other | -8,250 | 0 | -100.00 | ||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 8,250 | 8,250 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | -825,000 | 1,786,564 | -31.59 | ||||
2015-06-26 |
|
4 | ROKA |
Roka BioScience, Inc.
Stock Option (right to buy) |
A - Award | -15,000 | 15,000 | -50.00 | ||||
2015-06-19 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -48,796 | 0 | -100.00 | 16.02 | -781,800 | ||
2015-06-19 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -63,085 | 48,796 | -56.39 | 16.67 | -1,051,804 | 813,566 | |
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -55,105 | 111,881 | -33.00 | 16.85 | -928,668 | 1,885,497 | |
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 166,986 | 166,986 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 6,856 | 6,856 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 9,406 | 9,406 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 16,262 | 16,262 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 32,524 | 32,524 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -921,000 | 921,000 | -50.00 | ||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 921,000 | 921,000 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -3,000,000 | 7,641,250 | -28.19 | ||||
2015-06-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | 10,000 | 10,000 | |||||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock Warrant (right to buy) |
P - Purchase | 560,748 | 560,748 | 0.12 | 70,094 | 70,094 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 1,869,159 | 7,488,893 | 33.26 | 10.70 | 20,000,001 | 80,131,155 | |
2015-06-04 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -629 | 0 | -100.00 | 58.13 | -36,564 | ||
2015-06-04 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -1,500 | 629 | -70.46 | 57.55 | -86,332 | 36,202 | |
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 252 | 252 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 252 | 252 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 2,129 | 2,129 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -1,000,000 | 8,854,255 | -10.15 | ||||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -1,924 | 0 | -100.00 | 92.57 | -178,107 | ||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -500 | 1,924 | -20.63 | 91.86 | -45,932 | 176,746 | |
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,424 | 2,424 | |||||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 574 | 100.00 | ||||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 574 | 100.00 | ||||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -11,399 | 0 | -100.00 | ||||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 11,399 | 11,399 | |||||
2015-05-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1,139,891 | 1,139,890 | -50.00 | ||||
2015-05-11 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
U - Other | -2,384,221 | 0 | -100.00 | 46.00 | -109,674,166 | ||
2015-03-24 | 3 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
37,500,000 | ||||||||
2015-03-24 | 3 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
37,500,000 | ||||||||
2015-03-05 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Director Stock Option (Right to Buy) |
A - Award | 20,000 | 20,000 | |||||
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -5,373,396 | 0 | -100.00 | ||||
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 500,000 | 1,888,474 | 36.01 | 10.00 | 5,000,000 | 18,884,740 | |
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,388,474 | 1,388,474 | |||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 9/9/2013 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 12/2/2014 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 2/26/2014 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
P - Purchase | 23,457 | 2,158,539 | 1.10 | 11.00 | 258,027 | 23,743,929 | |
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
C - Conversion | 341,201 | 2,135,082 | 19.02 | 9.35 | 3,190,229 | 19,963,017 | |
2015-01-29 |
|
4 | BOX |
BOX INC
Class B Common Stock |
J - Other | 2,091,457 | 2,091,457 | |||||
2015-01-29 |
|
4 | BOX |
BOX INC
Series E Preferred Stock |
C - Conversion | -274,916 | 0 | -100.00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Series D2 Preferred Stock |
C - Conversion | -1,653,761 | 0 | -100.00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Existing Class A Common Stock |
J - Other | -2,091,457 | 0 | -100.00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Existing Class A Common Stock |
C - Conversion | 1,928,677 | 2,091,457 | 1,184.84 | ||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
1,793,891 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3,587,767 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
1,793,891 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3,587,767 | ||||||||
2015-01-22 | 3 | BOX |
BOX INC
Existing Class A Common Stock |
325,560 | ||||||||
2015-01-22 | 3 | BOX |
BOX INC
Existing Class A Common Stock |
325,560 | ||||||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
S - Sale | -1,972 | 0 | -100.00 | 21.28 | -41,961 | ||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
S - Sale | -296 | 0 | -100.00 | 21.54 | -6,377 | ||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
S - Sale | -296 | 5,619,734 | -0.01 | 21.54 | -6,377 | 121,076,607 | |
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 1,972 | 1,972 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 296 | 296 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 296 | 296 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2014-12-29 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) |
P - Purchase | 19,868,965 | 19,868,965 | |||||
2014-12-29 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
P - Purchase | 19,868,965 | 35,298,087 | 128.78 | 0.10 | 1,992,857 | 3,540,398 | |
2014-12-22 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -55,994 | 3,569,210 | -1.54 | 8.01 | -448,512 | 28,589,372 | |
2014-12-22 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -27,790 | 3,625,204 | -0.76 | 7.91 | -219,683 | 28,657,600 | |
2014-12-18 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -52,998 | 3,652,994 | -1.43 | 7.90 | -418,742 | 28,862,671 | |
2014-12-18 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -63,094 | 3,705,992 | -1.67 | 7.72 | -487,269 | 28,621,006 | |
2014-12-18 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -27,233 | 3,769,086 | -0.72 | 7.76 | -211,238 | 29,235,669 | |
2014-12-16 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -1,000,000 | 5,619,734 | -15.11 | ||||
2014-12-15 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -16,859 | 3,796,319 | -0.44 | 7.82 | -131,827 | 29,684,937 | |
2014-12-15 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -56,420 | 3,813,178 | -1.46 | 7.93 | -447,174 | 30,222,486 | |
2014-12-15 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -53,182 | 3,869,598 | -1.36 | 7.92 | -421,201 | 30,647,216 | |
2014-12-10 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -31,220 | 3,922,780 | -0.79 | 7.87 | -245,804 | 30,885,224 | |
2014-12-10 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -26,992 | 3,954,000 | -0.68 | 7.79 | -210,195 | 30,790,984 | |
2014-12-10 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -21,448 | 3,980,992 | -0.54 | 7.71 | -165,340 | 30,689,069 | |
2014-12-10 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 1,000,000 | 4,811,691 | 26.24 | 4.00 | 4,000,000 | 19,246,764 | |
2014-12-05 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -18,959 | 4,002,440 | -0.47 | 7.83 | -148,525 | 31,355,115 | |
2014-12-05 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -38,061 | 4,021,399 | -0.94 | 7.83 | -297,903 | 31,475,490 | |
2014-12-05 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -46,635 | 4,059,460 | -1.14 | 7.92 | -369,405 | 32,155,795 | |
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1,250,000 | 1,964,192 | -38.89 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 69,572 | 69,572 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 3,920 | 3,920 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 2,857 | 2,857 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 6,777 | 6,777 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 13,553 | 20,522 | 194.48 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -383,750 | 0 | -100.00 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 383,750 | 383,750 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -1,250,000 | 0 | -100.00 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1,250,000 | 1,250,000 | |||||
2014-12-02 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -61,569 | 4,106,095 | -1.48 | 7.90 | -486,432 | 32,440,614 | |
2014-12-02 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -24,796 | 4,167,664 | -0.59 | 7.89 | -195,519 | 32,862,447 | |
2014-12-02 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -50,500 | 4,192,460 | -1.19 | 7.99 | -403,515 | 33,499,432 | |
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 2,639 | 2,639 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 252 | 252 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 252 | 252 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -1,000,000 | 3,994,106 | -20.02 | ||||
2014-11-26 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -76,600 | 4,242,960 | -1.77 | 8.01 | -613,221 | 33,967,016 | |
2014-11-26 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -50,000 | 4,319,560 | -1.14 | 7.90 | -394,990 | 34,123,660 | |
2014-11-26 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -23,400 | 4,369,560 | -0.53 | 7.72 | -180,566 | 33,717,710 | |
2014-11-21 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -24,459 | 4,392,960 | -0.55 | 7.66 | -187,395 | 33,657,102 | |
2014-11-21 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -21,550 | 4,417,419 | -0.49 | 7.69 | -165,655 | 33,956,700 | |
2014-11-21 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -28,991 | 4,438,969 | -0.65 | 7.69 | -223,063 | 34,154,315 | |
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series C Preferred Stock |
C - Conversion | -382,840 | 0 | -100.00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series B Preferred Stock |
C - Conversion | -655,321 | 0 | -100.00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series A Preferred Stock |
C - Conversion | -2,378,408 | 0 | -100.00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Common Stock |
P - Purchase | 69,112 | 3,502,922 | 2.01 | 16.00 | 1,105,792 | 56,046,752 | |
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Common Stock |
C - Conversion | 3,416,569 | 3,433,810 | 19,816.54 | ||||
2014-10-02 | 3 | DERM |
Dermira, Inc.
Common Stock |
34,482 | ||||||||
2014-10-02 | 3 | DERM |
Dermira, Inc.
Common Stock |
34,482 | ||||||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Series C Preferred Stock |
C - Conversion | -58,692 | 0 | -100.00 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Series B Preferred Stock |
C - Conversion | -1,479,058 | 0 | -100.00 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Series A-2 Preferred Stock |
C - Conversion | -172,825 | 0 | -100.00 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
P - Purchase | 813,474 | 2,611,564 | 45.24 | 8.00 | 6,507,792 | 20,892,512 | |
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
C - Conversion | 58,692 | 1,798,090 | 3.37 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
C - Conversion | 1,479,058 | 1,739,398 | 568.13 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
C - Conversion | 260,340 | 260,340 | |||||
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -11,600 | 4,659,333 | -0.25 | 7.51 | -87,070 | 34,972,953 | |
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -146,800 | 4,670,933 | -3.05 | 7.87 | -1,154,846 | 36,745,296 | |
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -108,300 | 4,817,733 | -2.20 | 8.17 | -884,811 | 39,360,879 | |
2014-08-26 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -7,099 | 0 | -100.00 | 60.40 | -428,773 | ||
2014-08-25 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -27,921 | 7,099 | -79.73 | 61.02 | -1,703,739 | 433,181 | |
2014-08-25 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -24,391 | 35,020 | -41.05 | 60.46 | -1,474,680 | 2,117,309 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -8,712 | 0 | -100.00 | 59.89 | -521,728 | ||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -100 | 0 | -100.00 | 60.65 | -6,065 | ||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -4,939 | 100 | -98.02 | 59.49 | -293,811 | 5,949 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -343 | 0 | -100.00 | 59.70 | -20,478 | ||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -3,330 | 343 | -90.66 | 60.02 | -199,857 | 20,586 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -400 | 6,969 | -5.43 | 60.56 | -24,223 | 422,017 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10,055 | 7,369 | -57.71 | 59.73 | -600,618 | 440,175 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -9,348 | 59,411 | -13.60 | 59.79 | -558,917 | 3,552,184 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20,652 | 68,759 | -23.10 | 59.19 | -1,222,392 | 4,069,845 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1,607,096 | 3,214,192 | -33.33 | ||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 89,411 | 89,411 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 5,039 | 5,039 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 3,673 | 3,673 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 8,712 | 8,712 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 17,424 | 17,424 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -493,378 | 0 | -100.00 | ||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 493,378 | 493,378 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -1,607,096 | 0 | -100.00 | ||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1,607,096 | 1,607,096 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -384 | 0 | -100.00 | 36.94 | -14,185 | ||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -3,027 | 384 | -88.74 | 36.45 | -110,334 | 13,997 | |
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -325 | 0 | -100.00 | 35.93 | -11,676 | ||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -325 | 0 | -100.00 | 35.67 | -11,593 | ||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 3,411 | 3,411 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 325 | 325 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 325 | 406,825 | 0.08 | ||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | -12,900 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 12,900 | 12,900 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | -1,290,000 | 4,743,240 | -21.38 | ||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -2,641 | 0 | -100.00 | 26.19 | -69,174 | ||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -252 | 0 | -100.00 | 26.22 | -6,608 | ||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -252 | 0 | -100.00 | 26.26 | -6,616 | ||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 2,641 | 2,641 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 252 | 252 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 252 | 252 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -1,000,000 | 4,994,106 | -16.68 | ||||
2014-08-12 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -35,540 | 4,926,033 | -0.72 | 6.76 | -240,190 | 33,291,609 | |
2014-08-12 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -675,000 | 4,961,573 | -11.98 | 6.62 | -4,468,568 | 32,846,109 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,558,651 | 0 | -100.00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 230,769 | 1,789,420 | 14.81 | 13.00 | 2,999,997 | 23,262,460 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 1,558,651 | 1,558,651 | |||||
2014-08-01 |
|
4 | LOXO |
Loxo Oncology, Inc.
Director Stock Option (right to buy) |
A - Award | 15,625 | 15,625 | |||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series E Preferred Stock |
C - Conversion | -5,987,892 | 0 | -100.00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series D Preferred Stock |
C - Conversion | -8,555,784 | 0 | -100.00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series C Preferred Stock |
C - Conversion | -4,030,224 | 0 | -100.00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series B Preferred Stock |
C - Conversion | -12,360,000 | 0 | -100.00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
P - Purchase | 383,333 | 3,216,810 | 13.53 | 12.00 | 4,599,996 | 38,601,720 | |
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 542,381 | 2,833,477 | 23.67 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 801,741 | 2,291,096 | 53.83 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 365,056 | 1,489,355 | 32.47 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 1,119,565 | 1,124,299 | 23,649.45 | ||||
2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock |
9,468 | ||||||||
2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock |
9,468 | ||||||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -72,190 | 0 | -100.00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
J - Other | -468 | 72,190 | -0.64 | 14.00 | -6,552 | 1,010,660 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
X - Other | 72,658 | 72,658 | |||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock Purchase Warrant |
X - Other | -72,658 | 0 | -100.00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -216,573 | 0 | -100.00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
J - Other | -1,402 | 216,573 | -0.64 | 14.00 | -19,628 | 3,032,022 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
X - Other | 217,975 | 217,975 | |||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock Purchase Warrant |
X - Other | -217,975 | 0 | -100.00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -4,404,887 | 0 | -100.00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series A Preferred Stock |
C - Conversion | -1,415,642 | 0 | -100.00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 510,442 | 6,619,734 | 8.36 | 14.00 | 7,146,188 | 92,676,276 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 72,190 | 6,109,292 | 1.20 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 216,573 | 6,037,102 | 3.72 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 4,404,887 | 5,820,529 | 311.16 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 1,415,642 | 1,415,642 | |||||
2014-06-16 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | -12,414 | 12,414 | -50.00 | ||||
2014-06-16 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Director Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2014-06-09 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
S - Sale | -1,134 | 0 | -100.00 | 26.90 | -30,506 | ||
2014-06-09 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
S - Sale | -148 | 0 | -100.00 | 26.80 | -3,966 | ||
2014-06-09 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
S - Sale | -148 | 0 | -100.00 | 26.77 | -3,962 | ||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 1,134 | 1,134 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 148 | 148 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 148 | 148 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -5,000 | 0 | -100.00 | ||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 5,000 | 5,000 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -500,000 | 2,384,221 | -17.34 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (right to buy) |
C - Conversion | 55,831 | 55,831 | |||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (right to buy) |
C - Conversion | -55,831 | 0 | -100.00 | 15.81 | -882,470 | ||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -411,234 | 0 | -100.00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series D Preferred Stock |
C - Conversion | -1,236,487 | 0 | -100.00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series C Preferred Stock |
C - Conversion | -531,758 | 0 | -100.00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series B Preferred Stock |
C - Conversion | -383,249 | 0 | -100.00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series A Preferred Stock |
C - Conversion | -797,208 | 0 | -100.00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 411,234 | 3,943,269 | 11.64 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 1,236,487 | 3,532,035 | 53.86 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 531,758 | 2,295,548 | 30.15 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 383,249 | 1,763,790 | 27.76 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 797,208 | 1,380,541 | 136.66 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 583,333 | 583,333 | 12.00 | 6,999,996 | 6,999,996 | ||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Series C Preferred Stock |
C - Conversion | -1,123,596 | 0 | -100.00 | ||||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Series B Preferred Stock |
C - Conversion | -7,866,170 | 0 | -100.00 | ||||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Common Stock |
C - Conversion | 8,989,766 | 8,989,766 | |||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Series E Preferred Stock |
C - Conversion | -1,065,143 | 0 | -100.00 | ||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Series D Preferred Stock |
C - Conversion | -3,588,446 | 0 | -100.00 | ||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
C - Conversion | 4,653,589 | 4,673,589 | 23,267.94 | ||||
2014-03-27 | 3 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
40,000 | ||||||||
2014-03-27 | 3 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
40,000 | ||||||||
2014-03-13 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -14,500 | 0 | -100.00 | 95.34 | -1,382,475 | ||
2014-03-13 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20,500 | 14,500 | -58.57 | 94.28 | -1,932,767 | 1,367,079 | |
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -1,491 | 35,000 | -4.09 | 93.07 | -138,765 | 3,257,387 | |
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -11,433 | 36,491 | -23.86 | 91.05 | -1,041,007 | 3,322,608 | |
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10,700 | 47,924 | -18.25 | 90.62 | -969,620 | 4,342,811 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -7,702 | 58,624 | -11.61 | 96.13 | -740,368 | 5,635,332 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -22,146 | 66,326 | -25.03 | 95.42 | -2,113,081 | 6,328,555 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20,152 | 88,472 | -18.55 | 94.32 | -1,900,672 | 8,344,396 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -5,039 | 0 | -100.00 | 95.50 | -481,224 | ||
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -3,673 | 0 | -100.00 | 95.50 | -350,772 | ||
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -8,712 | 0 | -100.00 | 95.50 | -831,996 | ||
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -17,425 | 0 | -100.00 | 95.50 | -1,664,088 | ||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1,607,096 | 4,821,288 | -25.00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 89,428 | 108,624 | 465.87 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10,804 | 19,196 | -36.01 | 97.31 | -1,051,373 | 1,868,026 | |
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 5,039 | 5,039 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 3,673 | 3,673 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 8,712 | 8,712 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 17,425 | 17,425 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -493,378 | 0 | -100.00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 493,378 | 493,378 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -1,607,096 | 0 | -100.00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1,607,096 | 1,607,096 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10,000 | 30,000 | -25.00 | 96.00 | -960,012 | 2,880,036 | |
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20,000 | 40,000 | -33.33 | 95.14 | -1,902,702 | 3,805,404 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -6,516 | 60,000 | -9.80 | 97.11 | -632,769 | 5,826,600 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -14,874 | 66,516 | -18.27 | 96.70 | -1,438,316 | 6,432,097 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -16,547 | 81,390 | -16.90 | 95.54 | -1,580,900 | 7,776,001 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -80,819 | 97,937 | -45.21 | 94.47 | -7,634,971 | 9,252,108 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10,078 | 0 | -100.00 | 95.35 | -960,937 | ||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -7,346 | 0 | -100.00 | 95.45 | -701,180 | ||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -17,424 | 0 | -100.00 | 95.27 | -1,659,972 | ||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -34,848 | 0 | -100.00 | 94.90 | -3,307,009 | ||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -3,214,192 | 6,428,384 | -33.33 | ||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 178,756 | 178,756 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 10,078 | 10,078 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 7,346 | 7,346 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 17,424 | 17,424 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 34,848 | 34,848 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -986,757 | 0 | -100.00 | ||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 986,757 | 986,757 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -3,214,192 | 0 | -100.00 | ||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 3,214,192 | 3,214,192 | |||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series C Preferred Stock |
C - Conversion | -4,840,686 | 0 | -100.00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
C - Conversion | -1,462,857 | 0 | -100.00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
S - Sale | -487,143 | 1,462,857 | -24.98 | 1.13 | -549,984 | 1,651,566 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
X - Other | 550,000 | 1,950,000 | 39.29 | 1.00 | 550,000 | 1,950,000 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Warrants |
X - Other | -550,000 | 0 | -100.00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B Preferred Stock |
C - Conversion | -8,400,000 | 0 | -100.00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series A Preferred Stock |
C - Conversion | -6,000,000 | 0 | -100.00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 472,410 | 3,811,691 | 14.15 | 7.00 | 3,306,870 | 26,681,837 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 3,339,281 | 3,339,281 | |||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series E Convertible Preferred Stock |
C - Conversion | -612,089 | 0 | -100.00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series D Convertible Preferred Stock |
C - Conversion | -401,837 | 0 | -100.00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series C Convertible Preferred Stock |
C - Conversion | -2,242,087 | 0 | -100.00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 612,089 | 3,256,013 | 23.15 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 401,837 | 2,643,924 | 17.92 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 2,242,087 | 2,242,087 | |||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -56,983 | 0 | -100.00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -160,672 | 0 | -100.00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -749,721 | 0 | -100.00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -13,551 | 2,316,692 | -0.58 | 10.96 | -148,519 | 25,390,944 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 56,983 | 2,330,243 | 2.51 | 10.96 | 624,534 | 25,539,463 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -38,210 | 2,273,260 | -1.65 | 10.96 | -418,782 | 24,914,930 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 160,672 | 2,311,470 | 7.47 | 10.96 | 1,760,965 | 25,333,711 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -260,280 | 2,150,798 | -10.80 | 16.00 | -4,164,480 | 34,412,768 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 749,721 | 2,411,078 | 45.13 | 16.00 | 11,995,536 | 38,577,248 | |
2014-01-23 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Director Stock Option (Right to Buy) |
A - Award | 7,457 | 7,457 | |||||
2014-01-23 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -169,887 | 5,994,106 | -2.76 | 35.50 | -6,030,988 | 212,790,763 | |
2014-01-21 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -1,132,589 | 6,163,993 | -15.52 | 35.50 | -40,206,910 | 218,821,752 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Series A-1 Preferred Stock |
C - Conversion | -11,824,058 | 0 | -100.00 | ||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Series A-1 Preferred Stock |
C - Conversion | -11,250,850 | 0 | -100.00 | ||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 512,500 | 4,093,377 | 14.31 | 8.00 | 4,100,000 | 32,747,016 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
C - Conversion | 3,580,877 | 3,580,877 | |||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 487,500 | 4,481,758 | 12.21 | 8.00 | 3,900,000 | 35,854,064 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
C - Conversion | 3,407,283 | 3,994,258 | 580.48 | ||||
2014-01-13 |
|
4 | GLYC |
GLYCOMIMETICS INC
Stock Option (right to buy) |
A - Award | 15,401 | 15,401 | |||||
2014-01-09 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock |
586,975 | ||||||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -562 | 0 | -100.00 | 6.22 | -3,496 | ||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -1,452 | 0 | -100.00 | 6.22 | -9,031 | ||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 562 | 562 | |||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 1,452 | 1,452 | |||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -1,000,000 | 4,467,960 | -18.29 | ||||
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
S - Sale | -1,000 | 0 | -100.00 | 5.13 | -5,131 | ||
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Director Stock Option (right to buy) |
M - Exercise | -7,500 | 0 | -100.00 | ||||
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Director Stock Option (right to buy) |
M - Exercise | -7,500 | 0 | -100.00 | ||||
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
S - Sale | -15,000 | 0 | -100.00 | 5.38 | -80,754 | ||
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
M - Exercise | 7,500 | 15,000 | 100.00 | 4.16 | 31,200 | 62,400 | |
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
M - Exercise | 7,500 | 7,500 | 2.71 | 20,325 | 20,325 | ||
2013-11-22 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
S - Sale | -5,333 | 1,000 | -84.21 | 5.16 | -27,533 | 5,163 | |
2013-11-20 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1,152,625 | 9,642,576 | -10.68 | ||||
2013-11-20 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -1,152,625 | 0 | -100.00 | 62.72 | -72,298,403 | ||
2013-11-20 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1,152,625 | 1,152,625 | |||||
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 25,800 | 406,500 | 6.78 | 19.31 | 498,185 | 7,849,312 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 23,700 | 380,700 | 6.64 | 20.31 | 481,269 | 7,730,761 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 163,620 | 357,000 | 84.61 | 19.04 | 3,115,538 | 6,797,744 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 152,459 | 193,380 | 372.57 | 19.99 | 3,047,335 | 3,865,260 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 40,921 | 40,921 | 20.91 | 855,654 | 855,654 | ||
2013-11-14 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -6,756,077 | 10,795,201 | -38.49 | ||||
2013-11-14 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -6,756,077 | 0 | -100.00 | 62.72 | -423,774,930 | ||
2013-11-14 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 6,756,077 | 6,756,077 | |||||
2013-11-13 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -201,012 | 1,661,357 | -10.79 | 32.37 | -6,506,758 | 53,778,126 | |
2013-11-13 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -903,229 | 1,862,369 | -32.66 | 32.37 | -29,237,523 | 60,284,885 | |
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
S - Sale | -2,573 | 0 | -100.00 | 9.83 | -25,288 | ||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 508 | 508 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 254 | 254 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 107 | 107 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 147 | 147 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 2,573 | 2,573 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -14,390 | 0 | -100.00 | ||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 14,390 | 14,390 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -1,439,003 | 1,439,002 | -50.00 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 162 | 952 | 20.51 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 790 | 790 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 3,994 | 3,994 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 167 | 167 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 229 | 229 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 395 | 395 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -22,394 | 0 | -100.00 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 22,394 | 22,394 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -2,239,385 | 2,239,385 | -50.00 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 41,260 | 41,260 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 5,918 | 5,918 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 5,918 | 5,918 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -200,000 | 0 | -100.00 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 200,000 | 200,000 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -20,000,000 | 54,184,956 | -26.96 | ||||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,483 | 0 | -100.00 | 70.80 | -175,796 | ||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 287 | |||||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,483 | 2,483 | |||||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 287 | |||||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -11,399 | 0 | -100.00 | ||||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 11,399 | 11,399 | |||||
2013-09-13 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1,139,890 | 2,279,781 | -33.33 | ||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -543 | 0 | -100.00 | 7.23 | -3,926 | ||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -1,414 | 0 | -100.00 | 7.16 | -10,121 | ||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 543 | 543 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 1,414 | 1,414 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -9,650 | 0 | -100.00 | ||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 9,650 | 9,650 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -965,000 | 5,467,960 | -15.00 | ||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -27,595 | 0 | -100.00 | 9.77 | -269,628 | ||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -3,846 | 0 | -100.00 | 9.77 | -37,575 | ||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 27,595 | 27,595 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 3,846 | 3,846 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -130,000 | 0 | -100.00 | ||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 130,000 | 130,000 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -13,000,000 | 74,184,956 | -14.91 | ||||
2013-08-14 |
|
4 | CVT |
CVENT INC
Series A Preferred Stock |
C - Conversion | -7,296,582 | 0 | -100.00 | ||||
2013-08-14 |
|
4 | CVT |
CVENT INC
Common Stock |
C - Conversion | 7,296,582 | 7,296,582 | |||||
2013-07-18 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
D - Sale to Issuer | -5,833,213 | 0 | -100.00 | ||||
2013-06-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | -12,414 | 12,414 | -50.00 | ||||
2013-06-17 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Director Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2013-06-11 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -415 | 0 | -100.00 | 40.49 | -16,803 | ||
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Series B Preferred Stock |
C - Conversion | -16,899,721 | 0 | -100.00 | ||||
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 400,000 | 6,033,240 | 7.10 | 15.00 | 6,000,000 | 90,498,600 | |
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 5,633,240 | 5,633,240 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -3,583 | 0 | -100.00 | 39.00 | -139,726 | ||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 3,583 | 3,583 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 415 | 415 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -16,450 | 0 | -100.00 | ||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 16,450 | 16,450 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -1,645,000 | 9,854,255 | -14.31 | ||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,483 | 0 | -100.00 | 70.80 | -175,796 | ||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,483 | 2,483 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 287 | 287 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -11,399 | 0 | -100.00 | ||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 11,399 | 11,399 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1,139,890 | 2,279,781 | -33.33 | ||||
2013-06-04 |
|
4 | TRGT |
TARGACEPT INC
Stock Option (Right to Buy) |
X - Other | -1,000 | 0 | -100.00 | ||||
2013-06-04 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
X - Other | 1,000 | 6,333 | 18.75 | 0.08 | 75 | 475 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
C - Conversion | -44,249,588 | 0 | -100.00 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
S - Sale | -95,980 | 44,249,588 | -0.22 | 0.88 | -83,982 | 38,718,390 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
X - Other | 122,602 | 44,345,568 | 0.28 | 0.68 | 83,982 | 30,376,714 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Warrant to Purchase Series C Preferred Stock (right to buy) |
X - Other | -122,602 | 0 | -100.00 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
C - Conversion | 2,765,599 | 2,765,599 | |||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -2,000,000 | 17,551,278 | -10.23 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | 6,541,485 | 19,551,278 | 50.28 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Series B Common Stock |
C - Conversion | -6,541,485 | 0 | -100.00 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | 10,602,127 | 13,009,793 | 440.35 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Series A Preferred Stock |
C - Conversion | -10,602,127 | 0 | -100.00 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -2,000,000 | 0 | -100.00 | 28.83 | -57,660,000 | ||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 2,000,000 | 2,000,000 | |||||
2013-05-23 | 3 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
15,429,122 | ||||||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6,165,747 | 0 | -100.00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note |
C - Conversion | -633,219 | 0 | -100.00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Warrant (right to buy) |
C - Conversion | -156,250 | 0 | -100.00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 625,000 | 5,833,213 | 12.00 | 8.00 | 5,000,000 | 46,665,704 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 4,418,940 | 5,208,213 | 559.87 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 633,219 | 789,273 | 405.77 | 8.00 | 5,065,752 | 6,314,184 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
S - Sale | -196 | 156,054 | -0.13 | 8.00 | -1,568 | 1,248,432 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 156,250 | 156,250 | 0.01 | 1,562 | 1,562 | ||
2013-04-11 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note |
A - Award | 633,219 | 633,219 | |||||
2013-04-11 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Warrant (right to buy) |
A - Award | 156,250 | 156,250 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | -2,321,212 | 4,642,425 | -33.33 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 5,344 | 10,396 | 105.78 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 687 | 1,273 | 117.24 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 687 | 1,273 | 117.24 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23,212 | 0 | -100.00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 23,212 | 23,212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -2,321,212 | 0 | -100.00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
C - Conversion | 2,321,212 | 2,321,212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | -2,321,212 | 4,642,425 | -33.33 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 5,052 | 5,052 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 586 | 586 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 586 | 586 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23,212 | 0 | -100.00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 23,212 | 23,212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -2,321,212 | 0 | -100.00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
C - Conversion | 2,321,312 | 2,321,212 | -2,321,312.00 | ||||
2013-03-08 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
S - Sale | -510 | 0 | -100.00 | 12.97 | -6,615 | ||
2013-03-08 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
S - Sale | -148 | 0 | -100.00 | 12.97 | -1,920 | ||
2013-03-08 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
S - Sale | -2,792 | 0 | -100.00 | 12.96 | -36,187 | ||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series F Convertible Preferred Stock |
C - Conversion | -189,966 | 0 | -100.00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series E Convertible Preferred Stock |
C - Conversion | -681,458 | 0 | -100.00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series D Convertible Preferred Stock |
C - Conversion | -848,420 | 0 | -100.00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series C-1 Convertible Preferred Stock |
C - Conversion | -502,386 | 0 | -100.00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series C Convertible Preferred Stock |
C - Conversion | -2,256,540 | 0 | -100.00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Common Stock |
C - Conversion | 4,478,770 | 4,478,770 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 510 | 510 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 148 | 148 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 2,792 | 2,792 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -14,000 | 0 | -100.00 | ||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 14,000 | 14,000 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -1,400,000 | 2,878,005 | -32.73 | ||||
2013-02-07 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Director Stock Option (Right to Buy) |
A - Award | 8,722 | 8,722 | |||||
2012-10-30 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
S - Sale | -1,597,787 | 8,196,614 | -16.31 | 13.44 | -21,478,252 | 110,182,984 | |
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | 6,963,636 | 13,927,273 | 100.00 | ||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -6,963,636 | 0 | -100.00 | ||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | 6,963,637 | 6,963,637 | |||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -6,963,637 | 0 | -100.00 | ||||
2012-09-20 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
G - Gift | -2,673 | 1,333 | -66.72 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -64,634 | 0 | -100.00 | 27.67 | -1,788,494 | ||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 1,333 | 4,006 | 49.87 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -45,000 | 0 | -100.00 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 45,000 | 45,000 | |||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -4,500,000 | 9,038,379 | -33.24 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-1 Preferred Stock |
C - Conversion | -611,185 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -2,043 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -2,043 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
J - Other | -51,744 | 2,043 | -96.20 | 10.00 | -517,440 | 20,430 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
J - Other | -51,744 | 2,043 | -96.20 | 10.00 | -517,440 | 20,430 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
X - Other | 53,787 | 53,787 | |||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
X - Other | 53,787 | 53,787 | |||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy) |
X - Other | -53,787 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy) |
X - Other | -53,787 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock Warrant (right to buy) |
X - Other | -125,291 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -898,808 | 0 | -100.00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
P - Purchase | 500,000 | 2,884,221 | 20.97 | 10.00 | 5,000,000 | 28,842,210 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 177,481 | 2,384,221 | 8.04 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 180,459 | 2,206,740 | 8.91 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 434,096 | 2,026,281 | 27.26 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 2,043 | 1,592,185 | 0.13 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 2,043 | 1,592,185 | 0.13 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -51,119 | 1,588,099 | -3.12 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
X - Other | 125,291 | 1,639,218 | 8.28 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 898,808 | 1,513,927 | 146.12 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 611,185 | 615,119 | 15,535.97 | ||||
2012-07-25 | 3 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
3,934 | ||||||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Series B Preferred Stock |
C - Conversion | -5,253,859 | 0 | -100.00 | ||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Series A Preferred Stock |
C - Conversion | -5,134,285 | 0 | -100.00 | ||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1,111,111 | 11,499,255 | 10.70 | 13.50 | 14,999,998 | 155,239,942 | |
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
C - Conversion | 10,388,144 | 10,388,144 | |||||
2012-06-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | -12,414 | 12,414 | -50.00 | ||||
2012-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Director Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2012-06-11 |
|
4 | TRGT |
TARGACEPT INC
Director Stock Option (Right to Buy) |
A - Award | 7,500 | 7,500 | |||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series E Preferred Stock |
C - Conversion | -1,349,396 | 0 | -100.00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series D Preferred Stock |
C - Conversion | -1,111,435 | 0 | -100.00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series C Preferred Stock |
C - Conversion | -450,952 | 0 | -100.00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series B-1 Preferred Stock |
C - Conversion | -230,379 | 0 | -100.00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series B Preferred Stock |
C - Conversion | -1,135,843 | 0 | -100.00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
C - Conversion | 4,278,005 | 4,278,005 | |||||
2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -24,965,000 | 0 | -100.00 | ||||
2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,400,000 | 10,641,250 | 70.50 | 5.00 | 22,000,000 | 53,206,250 | |
2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 6,241,250 | 6,241,250 | |||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 2,074 | 2,673 | 346.24 | ||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -69,998 | 0 | -100.00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Series D Preferred Stock |
C - Conversion | -1,758,302 | 0 | -100.00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Series C Preferred Stock |
C - Conversion | -8,036,099 | 0 | -100.00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
C - Conversion | 9,794,401 | 9,794,401 | |||||
2012-03-30 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 5,000 | 15,000 | 50.00 | ||||
2012-03-30 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | -500,000 | 4,529,190 | -9.94 | ||||
2012-03-28 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2012-03-28 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | -1,000,000 | 5,029,190 | -16.59 | ||||
2012-03-16 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 69,998 | 16.67 | ||||
2012-03-16 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 13,538,379 | -6.88 | ||||
2012-03-13 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 9,998 | 59,998 | 20.00 | ||||
2012-03-13 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 14,538,379 | -6.44 | ||||
2012-03-09 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 925,154 | 4,584,311 | 25.28 | 5.70 | 5,273,378 | 26,130,573 | |
2012-03-07 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 50,000 | 25.00 | ||||
2012-03-07 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 15,538,379 | -6.05 | ||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
S - Sale | -119 | 0 | -100.00 | 18.76 | -2,232 | ||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 119 | 119 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -4,000 | 0 | -100.00 | ||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 4,000 | 4,000 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -400,000 | 2,020,219 | -16.53 | ||||
2012-03-01 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -455,360 | 6,029,190 | -7.02 | 11.42 | -5,199,164 | 68,839,483 | |
2012-02-29 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 40,000 | 33.33 | ||||
2012-02-29 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 16,538,379 | -5.70 | ||||
2012-02-28 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -334,457 | 6,484,550 | -4.90 | 11.40 | -3,812,810 | 73,923,870 | |
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 30,000 | 50.00 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 17,538,379 | -5.39 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 20,000 | 100.00 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 18,538,379 | -5.12 | ||||
2012-02-24 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -54,849 | 6,819,007 | -0.80 | 11.75 | -644,344 | 80,106,967 | |
2012-02-24 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -253,211 | 6,873,856 | -3.55 | 11.68 | -2,957,808 | 80,294,887 | |
2012-02-23 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2012-02-23 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 19,538,379 | -4.87 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock Warrant (Right to Buy) |
U - Other | -791,015 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock Warrant (Right to Buy) |
U - Other | -263,671 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -20,000 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -7,500 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -7,500 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -7,500 | 0 | -100.00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -746,596 | 0 | -100.00 | 26.00 | -19,411,496 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
J - Other | 746,596 | 746,596 | |||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -248,864 | 0 | -100.00 | 26.00 | -6,470,464 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
J - Other | 248,864 | 248,864 | |||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -78,689 | 0 | -100.00 | 26.00 | -2,045,914 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
J - Other | 78,689 | 78,689 | |||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -68,492 | 0 | -100.00 | 26.00 | -1,780,792 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -6,898,294 | 0 | -100.00 | 26.00 | -179,355,644 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -1,941,407 | 0 | -100.00 | 26.00 | -50,476,582 | ||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 300 | 599 | 100.33 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 20,538,379 | -4.64 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 299 | 299 | |||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 21,538,379 | -4.44 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -23,083 | 64,634 | -26.32 | 23.05 | -532,063 | 1,489,814 | |
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -604 | 0 | -100.00 | 22.19 | -13,403 | ||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 604 | 604 | |||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -20,000 | 0 | -100.00 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10,000 | 20,000 | 100.00 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1,000,000 | 22,538,379 | -4.25 | ||||
2012-02-03 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
A - Award | 20,000 | 20,000 | |||||
2012-01-20 |
|
4 | INHX |
INHIBITEX, INC.
Stock Option (right to buy) |
M - Exercise | -7,500 | 0 | -100.00 | ||||
2012-01-20 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
M - Exercise | 7,500 | 68,492 | 12.30 | 8.79 | 65,925 | 602,045 |